1621. Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles.
作者: Helen H N Yan.;Hoi Cheong Siu.;Siu Lun Ho.;Sarah S K Yue.;Yang Gao.;Wai Yin Tsui.;Dessy Chan.;April S Chan.;Jason W H Wong.;Alice H Y Man.;Bernard C H Lee.;Annie S Y Chan.;Anthony K W Chan.;Ho Sang Hui.;Arthur K L Cheung.;Wai Lun Law.;Oswens S H Lo.;Siu Tsan Yuen.;Hans Clevers.;Suet Yi Leung.
来源: Gut. 2020年69卷12期2165-2179页
Sporadic early-onset colorectal cancer (EOCRC) has bad prognosis, yet is poorly represented by cell line models. We examine the key mutational and transcriptomic alterations in an organoid biobank enriched in EOCRCs.
1622. Transmucosal diverticular myotomy for the treatment of oesophageal diverticula associated with spastic motility disorders.
Thoracic oesophageal diverticula are often associated with spastic motility disorders. Despite correction of the underlying motility disorder, in a subgroup of patients, symptoms persist, primarily regurgitation. Surgical diverticulectomy is then proposed; however, as the approach is thoracoscopic or via thoracotomy, it is associated with significant morbidity and cost. Descriptions of endoscopic techniques for the treatment of symptomatic midoesophageal diverticula are few. We propose the novel technique of diverticular myotomy (DM) to treat this disorder. In this case series, we describe two patients who successfully underwent DM with no adverse outcomes and excellent clinical results at 24-month follow-up.
1623. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms.
作者: Xi Jin.;Jiang-Shan Lian.;Jian-Hua Hu.;Jianguo Gao.;Lin Zheng.;Yi-Min Zhang.;Shao-Rui Hao.;Hong-Yu Jia.;Huan Cai.;Xiao-Li Zhang.;Guo-Dong Yu.;Kai-Jin Xu.;Xiao-Yan Wang.;Jue-Qing Gu.;Shan-Yan Zhang.;Chan-Yuan Ye.;Ci-Liang Jin.;Ying-Feng Lu.;Xia Yu.;Xiao-Peng Yu.;Jian-Rong Huang.;Kang-Li Xu.;Qin Ni.;Cheng-Bo Yu.;Biao Zhu.;Yong-Tao Li.;Jun Liu.;Hong Zhao.;Xuan Zhang.;Liang Yu.;Yong-Zheng Guo.;Jun-Wei Su.;Jing-Jing Tao.;Guan-Jing Lang.;Xiao-Xin Wu.;Wen-Rui Wu.;Ting-Ting Qv.;Dai-Rong Xiang.;Ping Yi.;Ding Shi.;Yanfei Chen.;Yue Ren.;Yun-Qing Qiu.;Lan-Juan Li.;Jifang Sheng.;Yida Yang.
来源: Gut. 2020年69卷6期1002-1009页
The SARS-CoV-2-infected disease (COVID-19) outbreak is a major threat to human beings. Previous studies mainly focused on Wuhan and typical symptoms. We analysed 74 confirmed COVID-19 cases with GI symptoms in the Zhejiang province to determine epidemiological, clinical and virological characteristics.
1625. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
作者: Minseok Albert Kim.;Seung Up Kim.;Dong Hyun Sinn.;Jeong Won Jang.;Young-Suk Lim.;Sang Hoon Ahn.;Jae-Jun Shim.;Yeon Seok Seo.;Yang Hyun Baek.;Sang Gyune Kim.;Young Seok Kim.;Ji Hoon Kim.;Won Hyeok Choe.;Hyung Joon Yim.;Hyun Woong Lee.;Jung Hyun Kwon.;Sung Won Lee.;Jae Young Jang.;Hwi Young Kim.;Yewan Park.;Gi-Ae Kim.;Hyun Yang.;Han Ah Lee.;Myeongseok Koh.;Young-Sun Lee.;Minkoo Kim.;Young Chang.;Yoon Jun Kim.;Jung-Hwan Yoon.;Fabien Zoulim.;Jeong-Hoon Lee.
来源: Gut. 2020年69卷12期2214-2222页
Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance. Whether NA discontinuation was as safe as NA continuation after NA-induced surface antigen of HBV (HBsAg) seroclearance was investigated in the present study.
1626. Adenoma detection by Endocuff-assisted versus standard colonoscopy in routine practice: a cluster-randomised crossover trial.
作者: David Karsenti.;Gaelle Tharsis.;Bastien Perrot.;Philippe Cattan.;Gilles Tordjman.;Franck Venezia.;Elie Zrihen.;Dominique Gillot.;Agnes Gillet.;Charles Hagege.;Joelle Samama.;Isabelle Etienney.;Jean-Philippe Lab.;Bernard Guigui.;Jacqueline Zago.;Bouchra Benkessou.;Pascal Burtin.;Maryan Cavicchi.
来源: Gut. 2020年69卷12期2159-2164页
Endocuff Vision (ECV) is the second generation of a device designed to improve polyp detection. The aim of this study was to evaluate its impact on adenoma detection rate (ADR) in routine colonoscopy.
1628. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis.
Gastric cancer is strongly associated with Helicobacter pylori (H. pylori). We conducted a previous systematic review and meta-analysis that suggested eradication therapy reduced future incidence of gastric cancer, but effect size was uncertain, and there was no reduction in gastric cancer-related mortality. We updated this meta-analysis, as more data has accumulated. We also evaluated impact of eradication therapy on future risk of gastric cancer in patients having endoscopic mucosal resection for gastric neoplasia.
1629. Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease.
作者: Justine Vily-Petit.;Maud Soty-Roca.;Marine Silva.;Margaux Raffin.;Amandine Gautier-Stein.;Fabienne Rajas.;Gilles Mithieux.
来源: Gut. 2020年69卷12期2193-2202页
Hepatic steatosis accompanying obesity is a major health concern, since it may initiate non-alcoholic fatty liver disease (NAFLD) and associated complications like cirrhosis or cancer. Intestinal gluconeogenesis (IGN) is a recently described function that contributes to the metabolic benefits of specific macronutrients as protein or soluble fibre, via the initiation of a gut-brain nervous signal triggering brain-dependent regulations of peripheral metabolism. Here, we investigate the effects of IGN on liver metabolism, independently of its induction by the aforementioned macronutrients.
1632. Treatment of severe acute malnutrition with oat or standard ready-to-use therapeutic food: a triple-blind, randomised controlled clinical trial.
作者: David Taylor Hendrixson.;Claire Godbout.;Alyssa Los.;Meghan Callaghan-Gillespie.;Melody Mui.;Donna Wegner.;Taylor Bryant.;Aminata Koroma.;Mark J Manary.
来源: Gut. 2020年69卷12期2143-2149页
We hypothesised that an alternative RUTF (ready-to-use therapeutic food) made with oats (oat-RUTF) would be non-inferior to standard RUTF (s-RUTF).
1634. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8+ T cells in mice.
作者: Lijuan Wang.;Lei Tang.;Yiming Feng.;Suying Zhao.;Mei Han.;Chuan Zhang.;Gehui Yuan.;Jun Zhu.;Shuyuan Cao.;Qian Wu.;Lei Li.;Zhan Zhang.
来源: Gut. 2020年69卷11期1988-1997页
Gut microbiota have been linked to inflammatory bowel disease (IBD) and colorectal cancer (CRC). Akkermansia muciniphila (A. muciniphila) is a gram-negative anaerobic bacterium that is selectively decreased in the faecal microbiota of patients with IBD, but its causative role and molecular mechanism in blunting colitis-associated colorectal cancer (CAC) remain inconclusive. This study investigates how A. muciniphila engages the immune response in CAC.
1636. Faecal virome transplantation decreases symptoms of type 2 diabetes and obesity in a murine model.
作者: Torben Sølbeck Rasmussen.;Caroline Märta Junker Mentzel.;Witold Kot.;Josué Leonardo Castro-Mejía.;Simone Zuffa.;Jonathan Richard Swann.;Lars Hestbjerg Hansen.;Finn Kvist Vogensen.;Axel Kornerup Hansen.;Dennis Sandris Nielsen.
来源: Gut. 2020年69卷12期2122-2130页
Development of obesity and type 2 diabetes (T2D) are associated with gut microbiota (GM) changes. The gut viral community is predominated by bacteriophages (phages), which are viruses that attack bacteria in a host-specific manner. The antagonistic behaviour of phages has the potential to alter the GM. As a proof-of-concept, we demonstrate the efficacy of faecal virome transplantation (FVT) from lean donors for shifting the phenotype of obese mice into closer resemblance of lean mice.
1637. Endosonography-guided gallbladder drainage versus percutaneous cholecystostomy in very high-risk surgical patients with acute cholecystitis: an international randomised multicentre controlled superiority trial (DRAC 1).
作者: Anthony Y B Teoh.;Masayuki Kitano.;Takao Itoi.;Manuel Pérez-Miranda.;Takeshi Ogura.;Shannon Melissa Chan.;Carlos Serna-Higuera.;Shunsuke Omoto.;Raul Torres-Yuste.;Takayoshi Tsuichiya.;Ka Tak Wong.;Chi-Ho Leung.;Philip Wai Yan Chiu.;Enders Kwok Wai Ng.;James Yun Wong Lau.
来源: Gut. 2020年69卷6期1085-1091页
The optimal management of acute cholecystitis in patients at very high risk for cholecystectomy is uncertain. The aim of the current study was to compare endoscopic ultrasound (EUS)-guided gallbladder drainage (EUS-GBD) to percutaneous cholecystostomy (PT-GBD) as a definitive treatment in these patients under a randomised controlled trial.
1639. Cirrhosis as new indication for statins.
In the recent years, there have been an increasing number of reports on favourable effects of statins in patients with advanced chronic liver disease. These include reduction in portal pressure, improved liver sinusoidal endothelial and hepatic microvascular dysfunction, decreased fibrogenesis, protection against ischaemia/reperfusion injury, safe prolongation of ex vivo liver graft preservation, reduced sensitivity to endotoxin-mediated liver damage, protection from acute-on-chronic liver failure, prevention of liver injury following hypovolaemic shock and preventing/delaying progression of cirrhosis of any aetiology. Moreover, statins have been shown to have potential beneficial effects in the progression of other liver diseases, such as chronic sclerosing cholangitis and in preventing hepatocellular carcinoma. Because of these many theoretically favourable effects, statins have evolved from being considered a risk to kind of wonder drugs for patients with chronic liver diseases. The present article reviews the current knowledge on the potential applications of statins in chronic liver diseases, from its mechanistic background to objective evidence from clinical studies.
|